Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II, double blind, intermittent dose, placebo controlled, randomised, two period crossover study to investigate the effect of inhaled doses of VR776 administered via Aspirair inhaler on IVELT (intravaginal ejaculatory latency time) measured by stop watch in male patients with premature ejaculation.

Next Previous
Trial Profile

Phase II, double blind, intermittent dose, placebo controlled, randomised, two period crossover study to investigate the effect of inhaled doses of VR776 administered via Aspirair inhaler on IVELT (intravaginal ejaculatory latency time) measured by stop watch in male patients with premature ejaculation.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clomipramine (Primary)
  • Indications Premature ejaculation
  • Focus Therapeutic Use
  • Sponsors Vectura

Most Recent Events

  • 20 Jul 2016 Status changed from active, no longer recruiting to completed.
  • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top